|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunosuppression included transient pan-T cell depletion and an anti-CD154-based maintenance regimen.
|
30821922 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, blockade of the CD40-CD154 interaction drives the conversion of CD4+ T cells to regulatory T cells that mediate immunosuppression.
|
31426619 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously reported successful induction of renal allograft tolerance in nonhuman primates (NHP) after an initial posttransplant period of conventional immunosuppression (delayed tolerance) using a nonmyeloablative conditioning regimen consisting of anti-CD154 and anti-CD8 mAbs plus equine antithymocyte globulin (Atgam) and donor bone marrow transplantation (DBMT).
|
29300231 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combination of anti-CD154 dAb and conventional immunosuppression synergized to effectively control allograft rejection (Median survival time 397 days).
|
28097811 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three monkeys received an IS regimen without anti-CD154 monoclonal antibody (mAb, transplant [Tpl]-control) and 11 received IS with anti-CD154 mAb (Tpl-aCD154).
|
28417501 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Allospecific CD154+T-cytotoxic memory cells (CD154+TcM) predict acute cellular rejection after liver transplantation (LTx) or intestine transplantation (ITx) in small cohorts of children and can enhance immunosuppression management, but await validation and clinical implementation.
|
26950712 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunosuppression (IS) was based on either CTLA4Ig or anti-CD154 costimulation blockade.
|
25209710 |
2016 |
|
Immunosuppression
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anti-PA, anti-BA, and anti-Gal antibodies in NHP recipients 1 month after PITX were detected in 5 (100%), 3 (60%), and 5 (100%), respectively, of the 5 recipients receiving various immunosuppression (IS) without CD40-CD154 blockade (group I) and in 0 (0%), 0 (0%), and 4 (16%), respectively, of the 25 recipients receiving IS with CD40-CD154 blockade and sirolimus (group II).
|
25641336 |
2016 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD40 ligand (CD40L, CD154) induces apoptosis of tumor cells and triggers several immune mechanisms, including a T-helper type 1 (T(H)1) response, which leads to activation of cytotoxic T cells and reduction of immunosuppression.
|
22396493 |
2012 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacological immunosuppression for GVHD prophylaxis and therapy, including unspecific approaches with corticosteroids or methotrexate (MTX), as well as more specific therapy with cyclosporin A (CsA), tacrolimus (FK506), sirolimus, mycophenolate mofetil (MMF), antithymocyte globulin (ATG), and monoclonal antibodies (MAbs) directed against CD3, CD25, CD52, cytotoxic T-lymphocyte antigen (CTLA)-4, CD40 ligand, or TNF-alpha, have been proven to be effective.
|
15449032 |
2004 |
|
Immunosuppression
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vitro stimulation of PBMCs revealed an impaired up-regulation of CD154 in patients receiving conventional immunosuppression compared to healthy controls.
|
11127303 |
2000 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
For protracted treatment, we showed that readministration of recombinant adenovirus vectors could be facilitated by transient immunosuppression using a monoclonal antibody against CD40 ligand (MR1).
|
10428212 |
1999 |